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The group III metabotropic glutamate (mGlu) receptors mGlu7 and mGlu8 are receiving increased
attention as potential novel therapeutic targets for anxiety disorders. The effects mediated by these
receptors appear to result from a complex interplay of facilitatory and inhibitory actions at different brain
sites in the anxiety/fear circuits. To better understand the effect of mGlu7 and mGlu8 receptors on
extinction of contextual fear and their critical sites of action in the fear networks, we focused on the
amygdala. Direct injection into the basolateral complex of the amygdala of the mGlu7 receptor agonist
AMN082 facilitated extinction, whereas the mGlu8 receptor agonist (S)-3,4-DCPG sustained freezing
during the extinction acquisition trial. We also determined at the ultrastructural level the synaptic
distribution of these receptors in the basal nucleus (BA) and intercalated cell clusters (ITCs) of the
amygdala. Both areas are thought to exert key roles in fear extinction. We demonstrate that mGlu7 and
mGlu8 receptors are located in different presynaptic terminals forming both asymmetric and symmetric
synapses, and that they preferentially target neurons expressing mGlu1a receptors mostly located
around ITCs. In addition we show that mGlu7 and mGlu8 receptors were segregated to different inputs to
a signiﬁcant extent. In particular, mGlu7a receptors were primarily onto glutamatergic afferents arising
from the BA or midline thalamic nuclei, but not the medial prefrontal cortex (mPFC), as revealed by
combined anterograde tracing and pre-embedding electron microscopy. On the other hand, mGlu8a
showed a more restricted distribution in the BA and appeared absent from thalamic, mPFC and intrinsic
inputs. This segregation of mGlu7 and mGlu8 receptors in different neuronal pathways of the fear circuit
might explain the distinct effects on fear extinction training observed with mGlu7 and mGlu8 receptor
agonists.
This article is part of a Special Issue entitled ‘Metabotropic Glutamate Receptors’.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Classical fear conditioning provides one of the most powerful
models for studying the neural mechanisms of fear and patholog-
ical anxiety, both in animals and humans (Mahan and Ressler,fax: þ43 512 9003 72300.
: þ81 564 595275.
oto), Francesco.ferraguti@i-
SNS), Laboratory for Integra-
e, Room TS-24, Bethesda, MD
-NC-ND license.2012). During fear conditioning, associations are formed between
an aversive stimulus and conditioned stimuli such as neutral
environmental cues that are on the whole characteristic for that
particular aversive situation. Re-exposure to the conditioned
stimulus in absence of the predicted punishment eventually leads
to fear extinction. Typically a fear response spontaneously recovers
with the passage of time indicating that the original fear memory
was not erased but complemented by a parallel inhibitory memory
trace encoding the safety of the conditioned stimulus in that
particular extinction context (Myers and Davis, 2007). Extinction of
conditioned fear represents the basic paradigm of current
exposure-based interventions in the therapy of human anxiety
disorders (Phelps et al., 2004).
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involve a distributed neuronal network comprising the hippo-
campus, thalamus and ventromedial prefrontal cortex (mPFC)
(Quirk and Mueller, 2008), which are strongly interconnected with
the amygdaloid complex (Pitkänen, 2000). The role of the mPFC
was proposed to ultimately control amygdala activity (Quirk and
Beer, 2006). In fact, stimulation of the infralimbic component (IL)
of the mPFC blocks the expression of conditioned fear, likely by
altering inhibitory networks within the amygdala (Amano et al.,
2010). Over the past decade evidence has accumulated pointing
to a critical role of the basolateral complex of the amygdala (BLA) in
the expression of contextual fear (Goosens and Maren, 2001;
Muller et al., 1997) and in the acquisition of extinction (Herry et al.,
2010). While enhanced activation of inhibitory circuits within the
BLA may constrain the impact of sensory inputs at principal
neurons, the intercalated cell clusters (ITCs) have been proposed to
act as an inhibitory gate between the BLA and the central nucleus
under cortical control, thus regulating amygdala output (Ehrlich
et al., 2009; Pape and Pare, 2010). ITCs have emerged as a pivotal
structure for inhibition of the expression of conditioned fear and for
the storage of extinction memory (Likhtik et al., 2008). Although in
recent years the cellular organization of the ITCs has been inten-
sively investigated (Busti et al., 2011; Geracitano et al., 2007;Manko
et al., 2011; Royer et al., 2000), many of the neural circuits and
neurochemical systems involving the ITCs remain unclear.
Anatomical evidence has shown that group III metabotropic
glutamate (mGlu) receptors are enriched in the amygdala and
particularly in association with the ITCs (Masugi et al., 1999).
Selective activation or blockade of thesemGlu receptorswas shown
to alter anxiety and fear responses (Swanson et al., 2005). In
particular, mGlu7-null mice showed a marked reduction in the
acquisition of appetitive and aversive conditioning (Callaerts-Vegh
et al., 2006; Masugi et al., 1999), as well as deﬁcits in the extinction
of conditioned emotional responses (Fendt et al., 2008; Goddyn
et al., 2008). Measures of anxiety in mGlu8-deﬁcient mice gave
rise to inconsistent results (Duvoisin et al., 2005; Gerlai et al., 2002;
Robbins et al., 2007). However, recent work revealed in these
animals robust deﬁcits in the expression of contextual conditioned
fear and chlordiazepoxide-induced facilitation of extinction (Fendt
et al., 2010).
Here, we investigated the potential inﬂuence of acute pharma-
cological activation of mGlu7 and mGlu8 receptors on extinction of
contextual fear. In addition, we carried out a detailed character-
ization of the synaptic distribution of these receptors in the neural
circuits within the amygdala likely implicated in the extinction of
fear conditioning. Large neurons present at the border of ITC clus-
ters and expressing the mGlu1a receptor (Busti et al., 2011) were
also analyzed as possible preferential targets of inputs containing
group III mGlu receptors.
2. Materials and methods
2.1. Animals
The reported studies were carried out on adult male C57Bl/6J mice (25e30 g).
Before use, the animals were housed in groups of ﬁve under controlled laboratory
conditions (12:12 h light/dark cycle with lights on at 07:00 h; 21  1 C; 60%
humidity) with food and water ad libitum for at least two weeks after delivery from
the supplier (Institut für Labortierkunde und egenetik, University of Vienna, Him-
berg, Austria or Japan SLC Inc., Hamamatsu, Japan). All experimental protocols were
approved by the Austrian Animal Experimentation Ethics Board (GZ66.011/58-BrGT/
2004 and GZ66.011/02-BrGT/2007) or by the National Institute for Physiological
Science’s Animal care and Use Committee in compliance with both the European
Convention for the Protection of Vertebrate Animals used for Experimental and
Other Scientiﬁc Purposes (ETS no. 123) and the European Communities Council
Directive of 24 November 1986 (86/609/EEC). The authors further attest that all
efforts were made tominimize animal suffering, the number of animals used, and to
use alternatives to in vivo techniques whenever available.2.2. Drug injections
Guide canulae (25 gauge,11mm in length), aimed to target the dorsal pole of the
BLA [1.2 mm caudal, 3.2 mm lateral and 4.0 mmventral to Bregma according to the
Franklin and Paxinos mouse brain atlas (2001)], were bilaterally implanted into the
skull of anaesthetised mice (n ¼ 51; 50 mg/kg i.p. sodium pentobarbital) and ﬁxed
with two stainless screws and dental cement. Seven days after surgery and 15 min
before the onset of the behavioural experiments, the stylets of the guide canulae
were replaced by injection microcanulae (31 gauge), which extended the guide
canulae by 1 mm, thus, reaching the BLA. (S)-3,4-DCPG (Tocris, Bristol, UK) and
AMN082 (synthesized internally at Novartis) were dissolved in artiﬁcial cerebro-
spinal ﬂuid (aCSF). Mice were randomly assigned to 3 treatment groups, which were
injected with either vehicle (aCSF), AMN082 (300 pmol) or (S)-3,4-DCPG (10 nmol)
in a volume of 0.1 ml per side at a rate of 0.05 ml/min. The microcanulae were left in
place for another 2 min.2.3. Contextual fear conditioning
After surgery, mice were housed in groups of two to three until testing. They
were handled once daily for three days and familiarised to the injection procedure.
Behavioural experiments were performed between 09:00 and 16:00 h. Fear acqui-
sition, extinction training and extinction recall were performed in two identical,
brightly illuminated (300 lux) conditioning chambers (26  30  32 cm; Coulbourn
Instruments, USA) with ﬂoors of stainless steel bars. The rods were connected to
a shock source and grid scrambler (Coulbourn Instruments, USA) for delivery of the
footshock used as unconditioned stimulus. The chambers were cleaned with water
after each use. Video cameras were mounted above each chamber for recording of
the animal’s behaviour during the exposure to the context.
For fear acquisition, mice were placed into the conditioning chamber and ﬁve
mild foot shocks (0.7 mA, 2 s) were delivered. A 2 min stimulus-free period
preceded, separated and followed the unconditioned stimulus presentations. After
24 and 48 h, animals were replaced into the same chamber for 30 min of extinction
training and 8 min of extinction recall in the absence of unconditioned stimulus
presentations, respectively. Each testing session was continuously recorded and the
freezing behaviour displayed by the mice was subsequently analyzed in 2 min bin
intervals for fear acquisition, in 1 min bin intervals for fear extinction or for the total
time interval for extinction recall, by an experienced observer blind to the treatment
groups. The simultaneous display of a horizontal position of the head, rigid hunched
position and stiffening/lifting of the tail by the mice was taken as freezing behaviour
(Fanselow, 1980).2.4. Locomotor activity in the conditioning chamber
Unconditioned mice were placed into the conditioning chamber and their
spontaneous activity was recorded for 30 min by a video camera positioned above
the chamber. The distance travelledwas registered by a tracking system (VideoMot2,
TSE Systems GmbH, Bad Homburg, Germany). In addition, the time each mouse
spent in freezing behaviour was analyzed as described above.
Possible effects of (S)-3,4-DCPG on motor coordination were tested on the
accelerating rotarod (TSE Systems GmbH, Bad Homburg, Germany) according to
a previous protocol with slight modiﬁcations (Singewald et al., 2004). Mice were
placed onto a slowly (4 rpm) rotating rod, which was then continuously accelerated
to 40 rpm within 5 min. Mice were given an intense training (3  3 with a 5 min
intertrial interval) on the ﬁrst day and further training sessions (1  3/day) on the
two following days. On day 4, mice were injected with either (S)-3,4-DCPG or aCSF
and given two test trials 20 and 40 min later, which corresponded to time points 5
and 25 min spent in the conditioning chambers. The latency to fall off the rod was
automatically recorded. The maximum time on the rotarod was set at 5 min.2.5. Histology and perfusions for immunocytochemistry
At the end of each behavioural experiment, animals were killed by an overdose
of pentobarbital and the exact injection sites were histologically established in
50 mm-thick brain sections stained with cresyl violet. Behavioural data were
analyzed only from those animals that were injected at the correct target sites.
For immunocytochemical light and electron microscopy experiments, mice
were deeply anesthetized by intraperitoneal injection of Thiopental (250 mg/kg, i.p.;
Sandoz, Kundl, Austria) and perfused transcardially with phosphate buffered saline
(PBS; 0.9% NaCl, pH 7.4) followed by ice-cold ﬁxative made of 4% w/v para-
formaldehyde and 15% v/v of a saturated solution of picric acid in phosphate buffer
(PB; 0.1 M, pH 7.4) for 15 min. For electron microscopy experiments, glutaraldehyde
was added to the ﬁxative at a ﬁnal dilution of 0.05% v/v just before the perfusion.
Brains were immediately removed from the skull, washed in 0.1 M PB and sliced
coronally in 40 (for light microscopy) or 50 mm (for electron microscopy) thick
sections, unless otherwise speciﬁed, on a Leica VT1000S vibratome (Leica Micro-
systems, Vienna, Austria). Sections were stored in 0.1 M PB containing 0.05% NaN3 at
6 C until immunocytochemical experiments were performed.
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For this study, 3 different polyclonal antibodies against mGlu1a have been used,
two of them raised in rabbit and one in Guinea pig. One of the rabbit polyclonal
antibodies against mGlu1awas raised to a bacterial fusion protein containing amino
acid residues 859e1199 of rat mGlu1a (Shigemoto et al., 1997). Immunoblot results
indicated that the antibodies do not react with other mGlu receptors or proteins
(Shigemoto et al., 1997). The second rabbit polyclonal antibody against mGlu1a was
raised against a synthetic peptide corresponding to the amino acids 1116e1130 of
the rat mGlu1a sequence (Diasorin, Stillwater, MN). Immunolabelling for this anti-
body was completely abolished by pre-adsorption with synthetic rat mGlu1a
(manufacturer’s technical information) and in brain sections of mice lacking the
mGlu1 receptor (Ferraguti et al., 2004). The Guinea pig polyclonal antibody against
mGlu1a was kindly provided by Prof. M. Watanabe (Dept. Anatomy, Hokkaido
University, Sapporo, Japan) andwas raised against a fusion protein containing amino
acid residues 945e1127 of mouse mGlu1a (Tanaka et al., 2000). Also for this anti-
body immunolabelling was completely abolished in brain sections of mice lacking
the mGlu1 receptor (Ferraguti et al., 2004).
The rabbit polyclonal anti-mGlu7a antibody was raised against a bacterial fusion
protein containing the amino acid residues 874e915 of rat mGlu7a (Shigemoto et al.,
1996, 1997). Immunoblot results and tests in heterologous expression systems
indicated that the antibody does not react with other mGlu receptors or proteins. No
immunolabelling was obtained in the brain of mice deﬁcient in mGlu7 protein
(Sansig et al., 2001).
The guinea pig polyclonal anti-mGlu8a antibody was raised against a synthetic
peptide corresponding to the last 23 amino acids of mouse mGlu8a (Kinoshita et al.,
1996). Immunoblot analysis showed an immunoreactive band of the expected
molecular weight, which disappeared after pre-adsorption of the antibody with the
immunogenic peptide (Kinoshita et al., 1996). No immunolabelling was obtained in
the brain of mice deﬁcient in mGlu8 protein (Ferraguti et al., 2005).
Guinea pig antibodies to the vesicular g-aminobutyric acid transporter (VGAT),
vesicular glutamate transporters (VGluT) 1 and 2 were generous gifts from Prof. M.
Watanabe (Hokkaido University).
Biotinylated goat anti-PHA-L was purchased from Vector laboratories (Burlin-
game, CA; Product No. BA-0224).
2.7. Immunoﬂuorescence experiments
Immunoﬂuorescent experiments were carried out according to previously
published procedures (Ferraguti et al., 2004) using slices obtained from 4 mice.
Brieﬂy, free-ﬂoating sections were incubated in blocking solution, composed of 20%
normal goat serum (NGS), 0.1% TritonX (TX), 0.9% NaCl in 50 mM Tris (pH 7.4) for 1 h
at room temperature (RT) and then in primary antibodies (see Table 1 for complete
listing and dilutions), in combination or alone, made up in TBS, 0.1% TX, and 1% NGS
for approximately 48 h (6 C). Subsequently, after extensive washes in TBS, sections
were incubated overnight (6 C) with a mixture of appropriate secondary antibodies
(see Table 1). Sections were thenwashed and mounted onto gelatin-coated slides in
Vectashield (Vector Laboratories, Burlingame, CA). To control for a possible cross-
reactivity between IgGs in double and triple immunolabeling experiments, some
sections were processed through the same immunocytochemical sequence, except
that only one primary antibody was applied; but the full complement of secondaryTable 1
List of the concentrations and combinations of primary and secondary antibodies.
Primary
antibody
Antigen/source Species Dilut
mGlu1a Bacterial fusion protein
(aa 859e1199, rat sequence)
Rabbit serum 1.0 mg
mGlu1a Synthetic peptide
(aa 1116e1130, rat sequence)
Rabbit IgG 1.0 mg
mGlu1a Fusion protein (aa 945e1127,
mouse sequence)
G. Pig IgG 1.0 mg
EM
mGlu8a Synthetic peptide corresponding
to the last 23
amino acids of the C-terminus of
the mouse mGlu8a
G. Pig IgG 1.0 mg
EM
mGlu7a Bacterial fusion protein (aa 874e915) Rabbit IgG 1.0 mg
EM
PHA-L Vector G. Pig IgG 5.0 mg
VGAT Fusion protein (aa 31e112, mouse sequence) G. Pig IgG 1.0 mg
VGluT1 Fusion protein (aa 511e560, rat sequence) G. pig IgG 1.0 mg
VGluT2 Fusion protein (aa 519e582, rat sequence) G. pig IgG 1.0 mg
Capital letters indicate reactions for pre-embedding electron microscopy, whereas smal
Abbreviations: Dnk, donkey; G. Pig, Guinea pig; Gt, goat, Rb, rabbit.antibodies was maintained. In addition, the secondary antibodies utilized were
highly pre-adsorbed to the IgGs of numerous species. Immunoﬂuorescence was
studied using a Zeiss AxioImager M1 microscope (Zeiss, Vienna, Austria) with epi-
ﬂuorescence illumination equipped with the following ﬁlter blocks: Cy2/Alexa488
(excitation ﬁlter band pass [BP] 480/40 nm; reﬂection short-pass ﬁlter 505 nm;
emission ﬁlter BP 527/30 nm) and Cy3 (excitation ﬁlter BP 545/25 nm; reﬂection
short-pass ﬁlter 570 nm; emission ﬁlter BP 605/70 nm). Images were displayed and
analyzed by the Openlab software (version 5.5.0; Improvision). Images were
acquired through an ORCA-ER CCD camera (Hamamatsu, Hamamatsu City, Japan).
Brightness and contrast were adjusted for thewhole framewith no part of the frame
modiﬁed independently in any way.
2.8. PHA-L injections
For labelling of projections from the intralaminar thalamus and mPFC to the BLA
and ITCs, as well as from BLA to ITCs, adult male mice (n ¼ 10) were injected
unilaterally with Phaseolus vulgaris leucoagglutinin (PHA-L) into these regions using
previously published procedures (Gu and Simerly, 1997). Brieﬂy, animals were
anesthetized with 7% chloral hydrate in 0.9% NaCl (0.5 ml/100 g bodyweight). A 2.5%
solution of PHA-L (Vector) in 0.1 M sodium phosphate buffer (pH 7.8) was delivered
iontophoretically into the posterior amygdala (Bregma 1.6, þ3.3 ML, 5.1 DV),
intralaminar thalamus (Bregma 1.0, 0 ML, 3.9 DV) or IL-mPFC
(Bregma þ2.0, þ0.2 ML, 2.5 DV) through a stereotaxically positioned glass
micropipette (tip diameter 15e20 mm), by applying a positive current (3.5e5 mA, 7 s
on/off intervals) for 10e30 min. After 5e14 day survival period, mice were deeply
anesthetized with sodium pentobarbital (50 mg/kg, i.p.) and perfused transcardially
as described in 2.5. Serial coronal sections (50 mm thick), from injection sites to
projection sites, were cut with a vibratome (Leica, Vienna, Austria). Every ﬁfth
section was used for immunocytochemical detection of PHA-L for light microscopy.
Sections were ﬁrst incubated in blocking buffer composed of 2% NGS in PBS for 1 h
and then overnight at RT with 5 mg/ml biotinylated anti-PHA-L (Vector) in PBS
containing 0.3% TX and 1% NGS. After extensive washes, the sections were incubated
in the ABC complex (1:100, Vector) made up in PBS containing 0.1% TX for 2 h fol-
lowed by diaminobenzidine (DAB) (0.5 mg/ml) and 0.003% H2O2, as the electron
donor, for 5e6 min. If the injection sites were correctly placed and projection sites
were strongly labelled, amygdala sections from these animals were processed for
pre-embedding electron microscopy.
2.9. Pre-embedding immunocytochemistry for electron microscopy
Pre-embedding immunocytochemistry experiments were carried out according
to previously published procedures (Sreepathi and Ferraguti, 2012). Brieﬂy, free-
ﬂoating sections were washed three times in 0.1 M PB, cryoprotected in 20% sucrose
made in 0.1 M PB overnight at 6 C. After removal of the sucrose, the sections were
freeze-thawed twice to allow antibody penetration and then incubated in 20% NGS
in TBS for 2 h at RT. After blocking, sections were exposed for w72 h at 6 C to
primary antibodies (see Table 1) made up in a solution containing 2% NGS in TBS.
After three washes in TBS, sections were incubated overnight at 6 C with the
appropriate secondary antibodies (Table 1). When a single primary antibody was
used, it was visualized either by horseradish peroxidase (HRP) or by nanogold-
silver-enhanced reaction. When more than one primary antibody was used, one ofion Secondary antibody Dilution Combinations
/ml EM Gt anti-Rb nanogold (Nanoprobes) 1:100 D, E, F, G
/ml LM Dnk anti-Rb Alexa488 (Invitrogen) 1:1000 d
/ml LM Dnk anti-G. Pig Alexa488 (Invitrogen) 1:1000 c
Gt anti-G. Pig nanogold (Nanoprobes) 1:100 H, I
Gt anti-G. Pig Biotinylated (Vector) 1:100 C
/ml LM Dnk anti-G. Pig Cy3 (Jackson) 1:400 b, d
Dnk anti-G. Pig Alexa488 (Invitrogen) 1:1000 e
Gt anti-G. Pig nanogold (Nanoprobes) 1:100 B, H
/ml LM Dnk anti-Rb Cy3 (Jackson) 1:400 a, c, e
Gt anti-Rb Biotinylated (Vector) 1:500 I
Gt anti-Rb nanogold (Nanoprobes) 1:100 A, C, D, E, F, G
/ml EM Gt anti-G. Pig Biotinylated (Vector) 1:100 G, H
/ml EM Gt anti-G. Pig Biotinylated (Vector) 1:100 F
/ml EM Gt anti-G. Pig Biotinylated (Vector) 1:100 D
/ml EM Gt anti-G. Pig Biotinylated (Vector) 1:100 E
l letters indicate reactions for immunoﬂuorescence.
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visualized by HRP reaction. Silver enhancement was always carried out ﬁrst. After
several washes with TBS, sections incubated with Fab fragment secondary anti-
bodies coupled to nanogold (1.4 nm) were extensively washed in milliQ water,
followed by silver enhancement of the gold particles with the HQ kit (Nanoprobes
Inc., Stony Brook, NY, USA) forw5e10 min. Sections were then washed extensively
in milliQ water and then with TB. Sections processed for the HRP reaction were
incubated in ABC complex (diluted 1:100; Vector) made up in TB either overnight at
6 C or at RT for 2 h and then washed in TB several times before the antigen/
antibody complex was visualized by means of the DAB-H2O2 reaction. Sections
were subsequently washed with 0.1 M PB and treated with 2% OsO4 in 0.1 M PB for
30 min at RT. After several washes with 0.1 M PB and then with milliQ water,
sections were contrasted with 1% uranyl-acetate in 50% ethanol for 30 min at RT,
making sure they were protected from light. Sections were washed with milliQ
water followed by graded ethanol and propylene oxide at RT. Sections were then
quickly transferred into weighting boats containing epoxy resin (Durcupan ACM-
Fluka, Sigma, Gillingham, UK) and kept overnight at RT. The following day, the
sections were transferred onto siliconized slides, coverslipped with ACLAR e ﬁlm
coverslips (Ted Pella, Inc., Redding, CA), and incubated for 3 days at 60 C. Blocks
containing speciﬁc nuclei of the amygdala were cut under a stereomicroscope and
re-embedded in epoxy resin. Ultrathin sections (70 nm) were cut using a diamond
knife (Diatome, Biel, Switzerland) on an ultramicrotome (Ultracut, Leica, Vienna,
Austria), collected on copper slot grids coated with pioloform (Agar, Stansted,
England) and analyzed with a transmission electron microscope (Jeol JEM-1010 or
Philips CM120).2.10. Statistical analysis
Behavioural data are presented as mean  s.e.m. during 1, 2 and 5 min time
periods in contextual fear conditioning and locomotor activity studies, respectively.
Absolute freezing times were transformed into percentage scores. Statistical analysis
of behavioural data was carried out by one-way ANOVA or two-way ANOVA with
repeated measures followed by a Fisher’s LSD test after a signiﬁcant omnibus value.
P-levels <0.05 were considered statistically signiﬁcant, while P < 0.08 was used to
indicate a trend towards signiﬁcance.Fig. 1. Effect of intra-BLA injection of AMN082 (grey circles) or (S)-3,4-DCPG (white circles) o
extinction recall. (A) Localisations of bilateral injection sites for AMN082 and (S)-3,4-D
to 1.46 mm)(Paxinos and Franklin, 2001) and in a representative photomicrograph. (B)
increasing freezing responses to the context (arrows indicate delivery of foot shocks). (C) In
training, whereas (S)-3,4-DCPG inhibited it. (D) In the recall test no differences in fear expres
mice were observed. N ¼ 10e11 per experimental group. aP < 0.08, *P < 0.05, **P < 0.01, *To determine the sample size required for establishing the lack of group III
mGlus in speciﬁc inputs we used prospectively Power analysis. Sample size was
obtained by testing for one proportion using the software Java Applets for Power and
Sample Size (Lenth, 2006-9). We assumed the frequency of PHA-L positive axon
terminals labelled for presynaptic mGlu receptors to be 20% and a presumed lack of
or occasional presence of receptors in these terminals to be 1%. We set the power to
0.90 and the alpha to 0.05; using these parameters Power analysis indicated
a minimal sample size (number of synapses to be analyzed) of 23.
To estimate whether the type of target and of synapse formed by mGlu7 and
mGlu8-containing terminals was different, the relative proportions were analyzed
with the c2 test using the GraphPad Prism software (version 5.0c; GraphPad Soft-
ware Inc., La Jolla, CA, USA).3. Results
3.1. Effect of (S)-3,4-DCPG and AMN082 on extinction of learned
contextual fear
In order to conﬁne the pharmacological activity of the mGlu7
receptor agonist AMN082 and mGlu8 receptor agonist (S)-3,4-
DCPG to amygdala networks, mice were bilaterally implanted
with microcanulae targeting the BLA (Fig. 1A). Seven days after
surgery, mice were subjected to contextual fear conditioning. Mice
exhibited no freezing behaviour in the context prior to the
presentation of the ﬁrst footshock (ﬁrst 2 min). Freezing levels
constantly increased during conditioning to reach a maximum of
approximately 40% (Fig. 1B). The maximum freezing level did not
differ among experimental groups (time effect: F5,150 ¼ 64.106,
P < 0.001; treatment effect: F2,30 ¼ 1.076, P ¼ 0.354) (Fig. 1B).
Twenty-four hours later, mice were randomly assigned to one of
the 3 treatment groups and received microinjections of eithern context-speciﬁc fear expression during fear conditioning, fear memory extinction and
CPG in the BLA are shown in sequential coronal drawings (from Bregma 0.82
During contextual fear conditioning animals of all 3 experimental groups displayed
tra-BLA injection of AMN082 facilitated the attenuation of freezing during extinction
sion to the conditioning context between vehicle-, (S)-3,4-DCPG- and AMN082-treated
*P < 0.001 drug-treated versus. vehicle-treated animals.
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extinction trial. A signiﬁcant treatment effect (F2,29 ¼ 8.028,
P ¼ 0.002), time effect (F29,841 ¼ 12.513, P < 0.001) and
treatment  time interaction (F58,841 ¼ 1.720, P < 0.001) was
observed on extinction of contextual fear conditioning. In the
conditioning context the initial freezing levels were similar in all 3
experimental groups (Fig. 1C). Freezing levels displayed by vehicle-
treated mice were consistently decreased after 10 min of context
exposure (P ¼ 0.004 versus 2 min) reaching less than 15% freezing
after 20 min of context exposure (Fig. 1C). The mGlu7 agonist
AMN082 accelerated the decline in freezing levels as their
percentage of freezing was signiﬁcantly attenuated already after
6 min of context exposure (P ¼ 0.017 versus 2 min) with an almost
full extinction after 12 min (Fig. 1C). In contrast, in mice injected
with (S)-3,4-DCPG freezing levels increased up to 70% within the
ﬁrst 3 min of context exposure (P < 0.001 versus 1 min) and stayed
high for another 15 min (Fig. 1C). After this time point, mice began
to show some reduction in freezing behaviour (P ¼ 0.036 versus
2 min) that, however, was incomplete and remained relative high
(w40%) till the end of the trial (Fig. 1C). Compared with control
animals, (S)-3,4-DCPG-injected mice displayed elevated fear
responses duringmost of the time of the extinction trial (Fig. 1C). At
retest, 24 h later, mice from all three experimental groups did not
differ in freezing levels displayed upon exposure to the condi-
tioning chamber (F2,27 ¼ 0.070, P ¼ 0.933; Fig. 1D).3.2. Effect of (S)-3,4-DCPG on motor performance
In order to exclude that the impaired extinction observed after
(S)-3,4-DCPG-administration could be due to an effect of the drug
on motor performance, we assessed the mice on the accelerating
rotarod. Animals bilaterally implanted with canulae improved their
motor performance over 15 training trials (data not shown). (S)-
3,4-DCPG- and vehicle-treated mice did not differ in the latency to
fall off the rod during the test trial at 20 min (p ¼ 0.916) and at
40 min after microinjections (treatment effect: F1,8 ¼ 0.011,
P ¼ 0.920; time effect: F1,8 ¼ 4.546, P ¼ 0.066; treatment  time
interaction: F1,8 ¼ 0.018, P ¼ 0.898) (Fig. 2A). These results indicate
no general motor-impairing properties produced by intra-BLA
application of (S)-3,4-DCPG. We then studied the spontaneous
locomotor activity in the conditioning chamber. Although mobility
scores, as indicated by the distance travelled in the testing chamber,
showed a clear tendency to be reduced in (S)-3,4-DCPG-treated
mice as compared with vehicle-treated controls, no statistically
signiﬁcant treatment effect (F1,8 ¼ 3.898, P ¼ 0.084) or
treatment  time interaction (F5,40 ¼ 2.312, P ¼ 0.062; Fig. 2B) was
observed. In contrast, vehicle- and (S)-3,4-DCPG-treated animals
differed in their freezing behaviour elicited by exposure to a novel
context (treatment effect: F1,8 ¼ 7.901, P ¼ 0.023; time effect:Fig. 2. Effect of intra-BLA injection of (S)-3,4-DCPG on locomotion. (A) (S)-3,4-DCPG did not
either 20 or 40 min before the accelerating rotarod test. (B) Although spontaneous locomo
reduced in (S)-3,4-DCPG-treated mice as compared with vehicle-treated controls, it did n
percentage of freezing time as compared with vehicle-treatment. N ¼ 5 per experimental gF5,40 ¼ 8.141, P < 0.001; treatment  time interaction: F5,40 ¼ 6.219,
P < 0.001). While vehicle-treated animals showed no freezing
responses to the conditioning context, (S)-3,4-DCPG induced per se
high levels of freezing, which declined over time and was absent
after 20 min spent in the conditioning chamber (Fig. 2C).3.3. Cellular and subcellular distribution of mGlu7a and mGlu8a in
the mouse amygdala
To elucidate the molecular and cellular underpinnings of the
behavioural effects of mGlu7 and mGlu8 receptor agonists injected
intra-amygdala, we have then investigated at both light and elec-
tron microscopic level the cellular and subcellular distribution of
these receptors using highly speciﬁc antibodies. We limited our
analysis to the most abundant splice variants, namely mGlu7a and
mGlu8a (Corti et al., 1998). However, this should not represent
a limitation as the main splice variants for these receptors are
generally coexpressed in the same brain regions (Corti et al., 1998;
Ferraguti et al., 2005). Immunostaining for mGlu7a receptors
appeared punctate, suggestive of a presynaptic location, and to
decorate the soma and dendrites of principal cells and interneurons
in the BLA as well as large neurons present at the outer border
between the BLA and ITC clusters (Fig. 3AeB). Similarly, mGlu8a
receptor labelling was particularly intense in boutons apposed to
the dendrites of these large neurons (Fig. 4). In the basal nucleus of
the amygdala (BA), mGlu7a immunoreactivity was much more
prevalent than mGlu8a, being most likely present in terminals of
local axon collaterals of pyramidal neurons. Double immunoﬂuo-
rescence experiments allowed us to identify the large neurons as
containing mGlu1a receptors (Fig. 3BeI), which correspond to
previously described large ITC neurons (Busti et al., 2011). The
presynaptic location of mGlu7a and mGlu8a receptors was then
established both in the BA and ITC by means of silver-intensiﬁed
immunogold pre-embedding electron microscopy. For both recep-
tors the labelling was restricted to the active zone of presynaptic
axon terminals (Figs. 3J, 4JeK), which formed either asymmetric
synapses on spines and dendrites or symmetric synapses on
dendrites and somata. The type and frequency of synapses onto
speciﬁc targets (namely spines, dendritic shafts or somata) was
then analyzed in both the BA and ITCs. In the BA, 68% of the
randomly-selected synapses (n ¼ 82) containing presynaptic
mGlu7a receptors were on spines, and of the remaining synapses,
that were mostly present on dendrites, 62% were asymmetric. In
the ITCs, mGlu7a positive terminals (n¼ 43) targeted spines in only
28% of the cases, and of the synapses on dendritic shafts 71% were
asymmetric. The axon terminals containing mGlu8a receptors in
the BA (n¼ 41) made mostly (56%) synaptic contacts with dendritic
shafts, 30% of which formed asymmetric synapses, whereas the
remaining synapses were on spines. In the ITC, only 21% of theinﬂuence motor coordination as indicated by the latency to fall off the rod when given
tor activity (assessed in 5 min time bins) in the conditioning chambers seemed to be
ot reach statistical signiﬁcance. (C) Intra-BLA injection of (S)-3,4-DCPG increased the
roup. *P < 0.05, **P < 0.01, **P < 0.001 (S)-3,4-DCPG- versus. vehicle-treated animals.
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for the mGlu8a receptor were on spines, similar to what observed
for mGlu7a positive inputs, and 61% of the mGlu8a-containing
synapses on dendrites were asymmetric. We could, therefore,
observe a signiﬁcant difference in the BA (P < 0.001, c2 test) in the
pattern of target innervation between mGlu7a and mGlu8a
receptor-containing axon terminals, whereas in ITCs no differences
were detected (P ¼ 0.22, c2 test). These data suggest that in the BA
these two mGlu receptors may be to a large degree segregated in
independent afferents, whereas in the ITCs they could at least in
part coexist.
In order to understand whether mGlu7a and mGlu8a receptors
indeed coexist in the same presynaptic axon terminals targeting
large ITC neurons, we performed double immunoﬂuorescent
experiments, which revealed a complex pattern of coexpression as
some labelled boutons showed coexistence between mGlu7a and
mGlu8a receptors whereas others appeared only labelled for
mGlu7a or mGlu8a receptors, respectively (Fig. 5).
To assess whether the synapses on large mGlu1aþ ITC neurons
and containing mGlu7a receptors in the presynaptic bouton were
glutamatergic or GABAergic, we carried out triple-immunopre-
embedding electron microscopy experiments. We used silver-
intensiﬁed immunogold reactions for detecting presynaptic
mGlu7a and postsynaptic mGlu1a receptors and immunoperox-
idase for visualizing VGluT1, VGluT2 or VGAT. Immunoreactivity for
mGlu7a was observed in GABAergic VGATþ inputs as well as in
both VGluT1 and VGluT2 glutamatergic afferents (Fig. 6). This
indicates the presence of mGlu7a receptors in afferents originated
from thalamic/hypothalamic areas as well as from the neocortex/
hippocampus and/or BLA.
3.4. mPFC projections to the amygdala lack presynaptic mGlu7a
and mGlu8a receptors
To identify the origin of the glutamatergic inputs containing
mGlu7a and mGlu8a receptors, we carried out tracing experiments
injecting iontophoretically in mice the sensitive anterograde tracer
PHA-L combined with pre-embedding immuno-electron micros-
copy for revealing the presence of mGlu7a or mGlu8a receptors in
the projections to the amygdala.
Because the mPFC plays a critical role in the expression and
consolidation of fear extinction (Quirk and Mueller, 2008), we have
injected PHA-L into the mPFC. To our knowledge, no tracing studies
describing the projection from the mPFC to the amygdala in the
brain of any mouse strain have been published. We show here two
cases, selected from a larger series of injections, in which the
injection site was mostly conﬁned to the IL-PFC (Fig. 7A). However,
as a few labelled neurons could be observed in the prelimbic
component of the mPFC, we will refer here our tracing as origi-
nating from the mPFC. Similar to the rat (McDonald et al., 1996;
Vertes, 2004), most of the ﬁbres appeared to reach the amygdala
through the medial forebrain bundle and then turning laterally
through the substantia innominata. Some ﬁbres were also observed
running along the external capsule. Projections from the mPFC
terminated mostly in the intermediate division of the BA, although
some labelled boutons could be observed in ITC clusters placed
along the intermediate capsule (Fig. 7B). Other portions of the
amygdala such as the bed nucleus of the stria terminalis intra-
amygdala, the medial nucleus and some of the superﬁcial nuclei
received also a relatively dense projection. Outside the amygdala,
dense terminal and non-terminal projections were observed in the
substantia innominata, nucleus accumbens, endopiriform nucleus,
mediodorsal thalamus and lateral hypothalamus.
By means of combined anterograde tracing and pre-embedding
immuno-electron microscopic methods, we have analyzedwhether mPFC terminals forming synapses onto BA and ITC
neurons possessed presynaptic mGlu7a or mGlu8a receptors, and
second whether terminals containing group III mGlu receptors
formed synapses with mGlu1a-expressing neurons in these areas.
mPFC terminals formed only asymmetric synapses most of which
(w95% in the BA; w98% in the ITC) with dendritic spines and the
remaining with dendritic shafts. As shown in Table 2, none of the
terminals immunolabeled for PHA-L showed immunoreactivity for
mGlu7a or mGlu8a receptors, suggesting that mPFC projections to
the ITC or BA do not contain these group III presynaptic mGlu
receptors (Fig. 7E and F).
3.5. Thalamic midline efferents to the amygdala contain
presynaptic mGlu7a, but not mGlu8a receptors
Similar to the mPFC, also for the thalamic output to the amyg-
dala no studies are available for the mouse brain. As thalamo-
amygdala projections in the rat originate largely from midline
nuclei (Ottersen and Ben-Ari, 1979; Su and Bentivoglio, 1990;
Turner and Herkenham, 1991), we have injected PHA-L into the
dorsal subdivision of the thalamicmidline. The two cases presented
here, selected from a larger series, showed little variability in the
pattern of terminal labelling, therefore the descriptions below are
representative for both animals. As shown in Fig. 8A, the tracer
injections involved mainly the paraventricular, intermediodorsal
and central medial nuclei. Labelled axons leaving the injection site
projected laterally to the inferior thalamic peduncles and entered
the amygdala from its rostral pole. The amygdaloid terminal zone
was particularly intense in the intermediate division of the BA,
moderate in the capsular and lateral divisions of the CE andweak in
the medial division of the CE (Fig. 8B). A few labelled axons were
also observed in the intermediate capsule and main nucleus of the
ITC (Fig. 8C). Outside the amygdala intense innervation was
observed in the dorso-medial striatum and moderate in the ventral
pallidum, accumbens, claustrumeendopiriform nucleus and
cingulate cortex.
A combined anterograde tracing and pre-embedding immuno-
electron microscopy approach was carried out also for PHA-L
labelled thalamic terminals. Thalamic terminals formed only
asymmetric synapses most of which (w90% in the BA;w95% in the
ITC) with dendritic spines, whereas the remaining were on
dendritic shafts. As shown in Table 2, approximately 23% of
thalamic PHA-L labelled terminals on spines in the ITC possessed
mGlu7a receptors presynaptically, 29% of which formed synapses
with mGlu1a immunopositive proﬁles. In the BA, 33% of thalamic
terminals with presynaptic mGlu7a receptors contacting dendrites
and 8% contacting spines were made with mGlu1a-labelled
neurons. Conversely, none of the terminals immunolabelled for
PHA-L showed immunoreactivity for mGlu8a receptors, suggesting
that also thalamic projections to the ITC or BA do not contain
presynaptic mGlu8 receptors (Table 2; Fig. 8).
3.6. Intrinsic projections of the BA possess mGlu7a but not mGlu8a
receptors
To investigate whether intrinsic projections from the BA possess
group III mGlus and target ITC neurons, we injected PHA-L ionto-
phoretically in the posterior parvicellular division of the BA (Fig. 9).
In the two cases presented here, the terminal zone of labelled axons
was most intense within the entire extent of the BA (Fig. 9C).
Several neurons were found intensely labelled for PHA-L also in
rostral areas of the BA and in the LA, possibly due to retrograde
transport of the tracer. A robust projection was observed in the
medial CEAwhereas the innervation of the ITC seemedmoderate to
weak and mostly conﬁned to the medial paracapsular cluster and
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terminalis to leave the amygdala.
For this pathway, PHA-L and mGlu receptor immuno-electron
microscopy was limited to the ITC (Fig. 9DeE). Although PHA-L
labelled BA terminals in the ITC formed approximately 86% of
synapses with dendritic spines, we observed a higher degree of
synapses on dendritic shafts (14%), when compared to the other
pathways analyzed. Of the shaft synapses 50% were symmetric,
suggesting that some labelled interneurons of the BA anterogradely
projected to the ITC. As shown in Table 2, w20% of BA labelled
terminals in the ITC possessed mGlu7a receptors presynaptically, of
these 50% were in boutons targeting the shafts and 24% the spines
of mGlu1a immunolabelled neurons. Conversely, BA inputs did not
contain mGlu8a receptors.
4. Discussion
A full understanding of how a pharmacological treatment
inﬂuences a speciﬁc behavioural response requires, among other
aspects, the identiﬁcation of the brain areas and neural circuitries
expressing the drug target. Here, we showed that the activation of
mGlu7 or mGlu8 receptors through speciﬁc agonists, administered
intra-amygdala before extinction training, produced different
effects on the conditioned response. The mGlu7 receptor agonist
AMN082 facilitated extinction acquisition, whereas activation of
mGlu8 receptors by (S)-3,4-DCPG prevented the reduction of the
freezing behaviour normally observed by the re-exposure of the
animals to the conditioning context in the absence of the uncon-
ditioned stimulus. Despite the relatively similar distribution of the
immunoreactivity for mGlu7a and mGlu8a receptors within the
BLA and ITCs (Masugi et al., 1999), our anatomical analysis at the
ultrastructural level now revealed how these two receptors are to
a signiﬁcant extent segregated to different inputs. As shown sche-
matically in Fig. 10, which tries to summarise our anatomical
ﬁndings, mGlu7a receptors were located primarily onto gluta-
matergic afferents either intrinsic to the BLA or extrinsic and arising
from the thalamus, but not the mPFC. On the other hand, mGlu8a
showed amore restricted distribution thanmGlu7a receptors in the
BA and appeared absent from the three pathways that have been
examined in this study. The identiﬁed segregation of these two
group III mGlu receptors into primarily distinct afferents corrobo-
rates the marked pharmacological difference caused by their
respective agonists on extinction training.
In the present study, the direct injection of AMN082 and (S)-3,4-
DCPG into the BLA pre-empted the complicated interpretation of
systemic administrations and removed the risk of confounding
actions of these compounds on peripheral group III mGlu receptors
(Julio-Pieper et al., 2011). Based on previous studies, we can assume
that the area inwhich these drugs have exerted their effect remains
probably restricted to less that 1 mm around the injection site
(Palazzo et al., 2008, 2011). Therefore, the effect of AMN082 and (S)-
3,4-DCPG should be conﬁned primarily if not exclusively to the BLA
and the surrounding ITCs. Moreover, we selected drug doses within
the range of those previously used in other studies and shown to
inducemarked behavioural or physiological effects (Marabese et al.,
2007; Palazzo et al., 2008). On the other hand, given the relatively
high concentration of AMN082 and (S)-3,4-DCPG in the vicinity ofFig. 3. Distribution of mGlu7a receptors in the amygdala and preferential targeting of large
mGlu7a receptor reactivity in the BLA and in particular around the Imp and IN clusters. Sca
labelling around this cluster, but not inside, can be better appreciated. (C) Immunoﬂuoresc
reactivity in the IN. Scale bar: 125 mm. (DeF) Low and (GeI) high magniﬁcation images dep
positive terminals. Scale bar: DeI 20 mm. (J) Pre-embedding immunogold/silver labelling for
selectively concentrated in the presynaptic active zone of axon terminals, which establish p
Scale bar: 500 nm. Abbreviations: BA, basal amygdala; d, dendrite; Imp, medial paracapsulthe injection site a possible off site effect, e.g. on other mGlu
receptors, cannot be ruled out. However, as the drugs were infused
into the BLA at a very low speed and 15 min prior to the extinction
training, we believe that signiﬁcant off site effects inﬂuencing
extinction training are unlikely.
Recently, group III mGlu receptors have received increasing
attention as potential novel targets for anxiety disorders (Swanson
et al., 2005). The overall effect mediated by these receptors appears
to result from a complex balance between facilitatory and inhibi-
tory actions that is dependent on their regulation of neurotrans-
mitter release directly at the active zone of axon terminals. Indeed,
we found that mGlu7a and mGlu8a receptors in the BLA and ITCs
are exclusively located presynaptically in both glutamatergic and
GABAergic terminals, similar to what observed in other brain areas
(Ferraguti and Shigemoto, 2006; Ferraguti et al., 2005).
Only in the last few years, the individual role of distinct group III
mGlu receptors has begun to emerge with the development of
subtype selective drugs (Nicoletti et al., 2011). This study shows
distinct roles of mGlu7 and mGlu8 in the expression of extinction
and concurs with previous reports in delineating different func-
tions for these receptors on a number of behavioural manifesta-
tions including painmodulation and anxiety (Marabese et al., 2007;
Palazzo et al., 2008; Ren et al., 2011).
4.1. Potential neural mechanisms underlying enhanced extinction
following intra-amygdala activation of mGlu7 receptors
Our behavioural ﬁndings, which demonstrate a facilitated
acquisition of extinction of contextual fear by AMN082, are in
agreementwith the observeddelayed extinction learning inmGlu7-
deﬁcient mice in both aversive and appetitive experimental para-
digms (Callaerts-Vegh et al., 2006; Goddyn et al., 2008), as well as
with the facilitated extinction of cue-induced fear-potentiated
startle (Fendt et al., 2008). However, systemic administration of
AMN082 in rats has been recently shown to attenuate within-
session extinction, but to facilitate between-session extinction
retention (Tothet al., 2012). The limited facilitatoryeffectofAMN082
on extinction acquisition observed in our study is likely due to the
use of already well extinguishing mice. Since these animals show
a very efﬁcient extinction recall, it is difﬁcult to demonstrate
a further reduction of the freezing. This view is supported by addi-
tional evidence obtained with oral administration of AMN082 to
129/SvImJ mice, an animal model of impaired extinction (Hefner
et al., 2008). In 129/SvImJ mice, AMN082 produced a signiﬁcant
improvement of both acquisition and consolidation of fear extinc-
tion (Whittle, Ferraguti and Singewald, personal communication).
Taken together our results substantiate the view that memories can
bemore easily inhibitedwhenmGlu7 receptors are activated (Fendt
et al., 2008). One of the main conclusions of our study is that the
facilitation of extinction occurs through the activation of mGlu7
receptors located within amygdala networks. Previous anatomical
evidence has demonstrated that in the BLA mGlu7 had the highest
density of all group III mGlu receptor subtypes (Corti et al., 1998;
Kinoshita et al., 1998; Masugi et al., 1999; Shigemoto et al., 1997).
Here, we reveal the precise localization of mGlu7 receptors in
afferents to the BA and ITCs. These were primarily glutamatergic
inputs originating from BA pyramidal neurons and the midlinemGlu1aþ ITC neurons. (A) Immunoﬂuorescence micrograph showing intense punctate
le bar: 500 mm. (B) This micrograph shows an enlarged view of the IN and the intense
ence micrograph taken at the same focal plane as (B) and showing mGlu1a receptor
icting mGlu1aþ dendrites and spines of large ITC neurons decorated by dense mGlu7a
mGlu7a receptors in the BA. Immunometal particles identifying mGlu7a receptors are
rimarily excitatory synapses with postsynaptic dendrites (solid arrowhead) and spines.
ar ITC cluster; IN, main ITC nucleus; LA, lateral amygdala; s, spine.
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Fig. 5. Colocalization between mGlu7a and mGlu8a receptors on the large dendrite of a neuron located adjacent to the main ITC nucleus. The immunoreactivity for mGlu7a (shown
in red) appears widespread whereas the immunoreactivity for mGlu8a (shown in green) is much more restricted and primarily decorates large dendrites. The insert shows a portion
of a dendrite at higher magniﬁcation. The arrow indicates a bouton labelled for both receptors, whereas the arrowheads point to boutons labelled only for mGlu7a or mGlu8a. Scale
bar: 20 mm.
Fig. 6. Glutamatergic and GABAergic axon terminals innervating large mGlu1aþ ITC neurons contain mGlu7a receptors at their active zone. (A) Electron micrograph of a double pre-
embedding immunoreaction in which a mGlu1aþ dendrite is revealed by horseradish peroxidase (HRP, diffuse electron dense reaction) whereas mGlu7a receptors are visualized by
silver-intensiﬁed nanogold. Immunometal particles are clearly visible in the active zone of presynaptic terminals. (BeC) Electron micrographs of a triple pre-embedding immu-
noreaction in which the immunoreactivity for VGluT2 is shown by HRP, whereas immunometal particles on the postsynaptic membrane reveal mGlu1a receptors, and immu-
nometal particles on the presynaptic membrane visualize mGlu7a receptors. Clear presynaptic labelling for mGlu7a receptors can be observed in the VGluT2þ (HRP) boutons
forming asymmetric synapses (indicated by a solid arrowhead) with mGlu1aþ dendrites. (D) This electron micrograph shows the presence of mGlu7a receptors (immunometal
particles) at the active zone of a VGluT1þ (HRP) axon terminal forming an asymmetric synapse (indicated by a solid arrowhead) with a mGlu1aþ dendrite. (E) In this electron
micrograph the presence of mGlu7a receptors (immunometal particles) can be observed at the active zone of a VGATþ (HRP) axon terminal forming a symmetric synapse (indicated
by an empty arrowhead) with a mGlu1aþ dendrite. Scale bars: 200 nm.
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high number of asymmetric synapses on dendrites made by mGlu7
receptor-containing axon terminals suggests that they may origi-
nate from other brain areas with a preferential targeting onto
dendrites. The BA and ITCs receive a prominent mesolimbic dopa-
minergic innervation (Fuxe et al., 2003). However, in vivo micro-
dialysis studies showed that systemicadministrationofAMN082did
not inﬂuence extracellular dopamine (DA) levels (Li et al., 2008).
Moreover, the ventral tegmental area and substantia nigra pars
compacta possess negligible levels ofmGlu7 receptormRNA (Ohishi
et al., 1995). Taken together these ﬁndings suggest that mGlu7
receptors are not present on DAergic terminals and that the facili-
tation of extinction by AMN082 is a DA-independent mechanism.
Evidence fromprevious studies indicates that themodulation of theFig. 4. Distribution of mGlu8a receptors in the amygdala and preferential targeting of large
receptor reactivity around the BLA and in particular enfolding ITC clusters. Scale bar: 500 m
labelling at the outer border of this cluster. Scale bar: 100 mm. (C) Likewise, intense mGlu8a
Low and (GeI) high magniﬁcation images depicting mGlu1aþ dendrites and spines of large I
15 mm. (J, K) Consecutive electron micrographs of a dendritic proﬁle receiving both excita
enriched in mGlu8a receptors (labelled by immunoglod particles) at their active zone. Scale
ITC cluster; IN, main ITC nucleus; LA, lateral amygdala; s, spine.noradrenergic systemwithin the BLA facilitates the expression and
consolidation of extinction of contextual fear conditioning (Berlau
and McGaugh, 2006; Morris and Bouton, 2007). The noradrenergic
innervation of the BLA arises mainly from the locus coeruleus in the
brain stem (Fallon et al., 1978; Pickel et al., 1974; Roder and Ciriello,
1993), a brain structure expressing very high levels of mGlu7
receptor transcripts (Ohishi et al., 1995). Moreover, noradrenergic
axons in the BLA form both asymmetric and symmetric synapses
primarily with dendrites (Li et al., 2001). Therefore, mGlu7 recep-
tors, besides glutamatergic andGABAergic terminals,maybe located
also presynaptically on noradrenergic afferents to the BA and ITCs.
Further studies addressing the distribution and role of mGlu7
receptors on the noradrenergic system in the amygdala are war-
ranted. The localization of mGlu7 receptors in a number of differentmGlu1aþ ITC neurons. (A) Immunoﬂuorescence micrograph showing intense mGlu8a
m. (B) This micrograph shows an enlarged view of the IN and the particularly intense
receptor labelling can be appreciated around the Imp cluster. Scale bar: 100 mm. (DeF)
TC neurons decorated by dense mGlu8a positive terminals. Scale bar: DeF, 20 mm; GeI,
tory (solid arrowhead) and inhibitory (open arrowhead) synapses by axon terminals
bar: 500 nm. Abbreviations: BA, basal amygdala; d, dendrite; Imp, medial paracapsular
Fig. 7. Projections of the medial prefrontal cortex to the amygdala lack presynaptic mGlu7a and mGlu8a receptors. (A) Photomicrograph showing a PHA-L injection site in the mPFC
(mouse #5). (B) Line drawings of coronal sections arranged caudorostrally showing the extent of the PHA-L injection in themPFC for the two selected cases. Each injection is illustrated
with a different shading pattern. Although both injections are preferentially located within the infralimbic mPFC a few labelled neurons could also be observed in the prelimbic area.
(C) Darkﬁeld photomicrograph showing the distribution of labelled ﬁbres in the amygdala. (D) Higher power photomicrograph showing mPFC labelled axons in the Imp and inter-
mediate division of the BA. (E) Electron micrograph of a PHA-L-labelled mPFC terminal (ﬁlled by a dark electron dense reaction product) immunonegative for mGlu7a receptor and
forming an asymmetric synapse (indicated by an arrowhead) with a small dendrite of an ITC neuron in the Imp. Nearby a large terminal shows an intense mGlu7a receptor labelling
(immunometal particles) at its active zone. This terminal forms an asymmetric synapse (indicated by an arrowhead) with a small dendrite and lacks PHA-L labelling. (F) Electron
micrograph of a PHA-L-labelledmPFC terminal (ﬁlled by a dark electron dense reaction product) immunonegative formGlu8a receptor and forming an asymmetric synapse (indicated
by an arrowhead) with a dendritic spine of an ITC neuron in the Imp. Abbreviations: BA, basal nucleus of the amygdala; CEA, central nucleus of the amygdala; fmi, forcepsminor corpus
callosum; Imp, medial paracapsular cluster; LA, lateral nucleus of the amygdala; Scale bars: A, 500 mm; C, 200 mm; D, 100 mm; E, 200 nm; F, 500 nm.
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behavioural effects elicited byAMN082 to a deﬁnite network. On the
other hand, our study conﬁnes the presence of mGlu7 receptors to
a few deﬁned inputs and rules out an action of AMN082 on mPFC
inputs, and in particular those of the IL-PFC known to be important
for the long-term storage of fear extinction memories (Quirk and
Mueller, 2008).
The facilitation of extinction acquisition mediated by AMN082,
besides being possibly due to an activity-dependent depression ofneurotransmission (Perroy et al., 2002; Ugolini et al., 2008), could
also be ascribed to a functional blockade of mGlu7 receptors. In fact,
it has been shown that AMN082 in addition to stimulating can
induce the internalization of mGlu7 receptors (Pelkey et al., 2007).
However, since the selective downregulation of mGlu7 receptor
mRNA expression by means of short interfering RNAs inhibited the
extinction of fear-potentiated startle, whereas AMN082 given
systemically facilitated extinction of conditioned fear (Fendt et al.,
2008), a functional blockade of the receptor appears unlikely.
Table 2
Quantitative evaluation of PHA-L-labelled inputs containing mGlu7a or mGlu8a receptors and their respective targets in the ITCs and BA.
PHA-L-positive boutons
mGlu7aþ mGlu8aþ On mGlu1aþ proﬁles mGlu7aþ on mGlu1aþ proﬁles
% (n) % (n) % (n) % (n)
Inputs to ITCs
mPFC projections Dendrites 0% 0/1 0% 0/2 0% 0/3 e
Spines 0% 0/61 0% 0/35 9% 9/96 0% 0/6
Thalamic projections Dendrites 0% 0/2 0% 0/1 0% 0/3 0% 0/1
Spines 23% 10/44 0% 0/16 38% 23/60 29% 5/17
BA projections Dendrites 20% 1/5a 0% 0/12a 29% 5/17 50% 1/2
Spines 20% 12/61 0% 0/45 37% 39/106 24% 9/38
Inputs to BA
mPFC projections Dendrites 0% 0/2 e e 0% 0/1 0% 0/1
Spines 0% 0/37 0% 0/31 18% 12/68 0% 0/9
Thalamic projections Dendrites 29% 2/7 0% 0/5 25% 3/12 33% 1/3
Spines 7% 5/71 0% 0/48 24% 29/119 8% 2/25
Soma 0% 0/1 e e e
(n) Number of positive proﬁles over the overall number of synapses observed.
Data have been collected from 2 animals for each pathway and at least 2 blocks per animal.
a For PHA-L-labelled BA projections also symmetric synapses on dendrites have been observed. In particular, n ¼ 1 in the reaction for mGlu7a and n ¼ 2 in that for mGlu8a.
Fig. 8. Thalamic midline efferents to the amygdala contain presynaptic mGlu7a, but not mGlu8a receptors. (A) Photomicrograph showing a PHA-L injection site in the thalamic
midline nuclei (mouse #3). (B) Line drawings of a coronal section showing the extent of the PHA-L injection in the thalamus for the two selected cases. Each injection is illustrated
with a different shading pattern. Both injections largely overlap and are primarily located within the paraventricular, intermediodorsal and central medial thalamic nuclei. (C)
Darkﬁeld photomicrograph showing the distribution of PHA-L-labelled ﬁbres in the amygdala. The terminal zone appears predominantly intense in the intermediate subdivision of
the BA, moderate in the lateral division of the central nucleus and a few labelled axons can be observed in the main ITC nucleus and in the intermediate capsule. (D) Electron
micrograph of a PHA-L-labelled thalamic terminal (ﬁlled by a dark electron dense reaction product) immunopositive for mGlu7a receptor (immunometal particles are visible at the
active zone) and forming an asymmetric synapse (indicated by an arrowhead) with a large spine of a BA neuron. Nearby another axon terminal also showing presynaptic mGlu7a
receptor labelling (immunometal particles) forms an asymmetric synapse (indicated by an arrowhead) with a small spine and lacks PHA-L labelling. This spine shows immunometal
particles at its plasma membrane indicative of mGlu1a receptor labelling. (F) Electron micrograph of a PHA-L-labelled thalamic axon terminal (ﬁlled by a dark electron dense
reaction product) immunonegative for mGlu8a receptor and forming two asymmetric synapses (indicated by arrowheads) with dendritic spines of an ITC neuron in the IN.
Abbreviations: BA, basal nucleus of the amygdala; CEA, central nucleus of the amygdala; Imp, medial paracapsular ITC cluster; IN, main ITC nucleus; LA, lateral nucleus of the
amygdala. Scale bars: A, 500 mm; C, 200 mm; D, 200 nm; E, 250 nm.
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Fig. 9. Intrinsic projections of the basolateral amygdala possess mGlu7a but not mGlu8a receptors. (A) Photomicrograph showing a PHA-L injection site in the caudal portion of the
BA (mouse #2). (B) Line drawings of coronal sections arranged rostrocaudally showing the extent of the PHA-L injection in the BA for the two selected cases. Each injection is
illustrated with a different shading pattern. (C) Darkﬁeld photomicrograph showing the distribution of PHA-L-labelled ﬁbres in the amygdala. The terminal zone appears
predominantly intense in the BA, where a number of retrogradely labelled neurons can also be observed. A large number of PHA-L-labelled ﬁbres enter the stria terminalis. (D) Serial
electron micrographs of a PHA-L-labelled BA axon terminal (ﬁlled by a dark electron dense reaction product) intensely immunopositive for mGlu7a receptor (immunometal
particles are visible at the active zone) and forming an asymmetric synapse (indicated by an arrowhead) with a small dendrite of an Imp ITC neuron also immunoreactive for the
mGlu1a receptor (immunometal particles are visible at the plasma membrane outside the postsynaptic density; arrows). (E) Serial electron micrographs of a PHA-L-labelled BA
axon terminal (ﬁlled by a dark electron dense reaction product) immunonegative for mGlu8a receptor and forming an asymmetric synapse (indicated by a solid arrowhead) with
a dendrite of an ITC neuron in the Imp. The same dendrite also receives a mGlu8a receptor-labelled bouton forming a symmetric synapse (indicated by an empty arrowhead).
Abbreviations: AStr, amygdalaestriatum transition zone; BA, basal nucleus of the amygdala; IN, main ITC nucleus; LA, lateral nucleus of the amygdala; opt, optic tract; st, stria
terminalis. Scale bars: A, 500 mm; C, 200 mm; D, 200 nm; E, 500 nm.
A. Dobi et al. / Neuropharmacology 66 (2013) 274e2892864.2. Potential neural mechanisms underlying impaired extinction
following intra-amygdala activation of mGlu8 receptors
The present study demonstrates that (S)-3,4-DCPG, when
injected intra-amygdala, precluded the attenuation of the freezing
response during the extinction training in mice, but did not prevent
the formation and consolidation of an extinction memory since the
level of freezing in extinction recall was comparable to the control
group. (S)-3,4-DCPG also caused a reduced spontaneous locomotor
activity and a short lasting immobility that was not due to motor
impairment or sedation, as indicated by the rotarod test. These
behavioural effects suggest an anxiogenic-like activity of (S)-3,4-
DCPG that inﬂuenced fear behaviour and concealed the behav-
ioural expression of fear extinction rather than impairing it.Interestingly, this seems in line with the impaired fear extinction
shown by animals characterized by enhanced trait anxiety (Muigg
et al., 2008), which also closely mirrors ﬁndings in anxiety
patients (Lissek et al., 2005). At odds with our ﬁndings, (S)-3,4-
DCPG was found to exert anxiolytic-like activity when given
systemically in mice (Duvoisin et al., 2010). However, systemic
application of (S)-3,4-DCPG might have inﬂuenced a number of
areas other than the BLA (Gosnell et al., 2011), and thus yielded
a different net effect compared to a local injection. No help for
interpretation of our data can be gained from studies on anxiety-
like behaviour in mGlu8-deﬁcient mice as they gave rise to
largely conﬂicting results. In fact, some of these studies reported an
anxiogenic-like phenotype in mGlu8-null mice (Duvoisin et al.,
2005; Linden et al., 2002; Robbins et al., 2007), whereas others
Fig. 10. Schematic representation of the pathways arising from the dorsal subdivision
of the thalamic midline nuclei (green), medial prefrontal cortex (mPFC, light blue) or
caudal portion of the basal nucleus of the amygdala (BA, red) by means of anterograde
tracing, and targeting: pyramidal neurons (Py) and interneurons expressing mGlu1a
receptors (I) in the BA; or medium-spiny (s) and large (L) mGlu1aþ neurons in the
ITCs. The size of the inputs is roughly proportional to their relative density. The
selective presence of presynaptic mGlu7a receptors at speciﬁc pathways is shown by
a light brown contour (as indicated by arrows). The respective frequency of asym-
metric synapses on spines or dendrites as well as symmetric synapses formed by
presynaptic axon terminals containing mGlu7a or mGlu8a receptors in the ITCs (upper
pie diagrams) and BA (lower pie diagrams) is also shown.
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2010; Gerlai et al., 2002). Injection of (S)-3,4-DCPG in the rat BLA
showed no effect in the elevated plus maze and Vogel test (Palazzo
et al., 2008; Stachowicz et al., 2005), but spontaneous locomotor
activity and extinction of fear conditioning were not analyzed.
Although these data might question an effect of (S)-3,4-DCPG on
measures of anxiety upon local infusion in the BLA, we cannot
exclude that differences in doses, tests used and species contrib-
uted to these apparently incongruous ﬁndings.
Our study reveals a more restricted distribution of mGlu8a in
the BLA compared to mGlu7a receptors, but a similarly intense
decoration of large mGlu1aþ neurons at the border of ITC clusters.
None of the traced pathways appeared to contain detectable
amounts of mGlu8a receptors, thus leaving still open the precise
identiﬁcation of the source of the inputs enriched in these recep-
tors. Therefore, even though we cannot conﬁne the behavioural
effects of (S)-3,4-DCPG to a deﬁnite amygdala network, our work
suggests that the mGlu8a-containing inputs forming asymmetric
synapses mostly arise from areas extrinsic to the amygdala, whichcould include the somatosensory, perirhinal and/or piriform cortex
or the ventromedial nucleus of the hypothalamus. In fact, among
the few areas expressing signiﬁcant amounts of mGlu8a mRNA
(Corti et al., 1998; Saugstad et al., 1997), these appear the only ones
to provide a signiﬁcant source of axons to the BLA (Pitkänen,
2000). On the other hand, the large percentage of symmetric
synapses on dendrites of BLA neuronsmade bymGlu8a-containing
inputs may derive from local interneurons, consistent with the
moderate expression of mGlu8a mRNA in the BLA (Corti et al.,
1998). Further tracing studies combined with immuno-electron
microscopy are needed to ﬁnally reveal the exact source of
mGlu8þ inputs.
4.3. Selective targeting of mGlu1aþ large ITC neurons by axon
terminals enriched in mGlu7a and/or mGlu8s receptors
One of the main ﬁndings of this work is the selective targeting
by axon terminals enriched in group III mGlu receptors of the large
mGlu1aþ neurons found at the border of ITC clusters (Busti et al.,
2011). The extensive dendritic arbors of these neurons mostly
align along the intermediate capsule and are probably capable of
receiving and integrating a large variety of inputs. Most of these
inputs appear to contain mGlu7a and/or mGlu8a receptors. Indeed,
we have shown that the mGlu7a receptor is present in both
GABAergic and glutamatergic afferents, and that the latter ones
form synapses primarily with the dendritic shafts, in agreement
with the poorly-spiny nature of these ITC neurons.
Interestingly, both short- and long-term extinction, but not fear
acquisition, was found impaired after injection of a mGlu1 receptor
antagonist into the BLA (Kim et al., 2007). Moreover, systemic
pharmacologic blockade of mGlu1 receptors before extinction
retrieval facilitated relapse phenomena, such as renewal and rein-
statement (Clem and Huganir, 2010). Taken together these data
suggest that the activity of mGlu1 receptors is linked speciﬁcally to
mechanisms underlying fear extinction. Although the exact cellular
and molecular mechanisms underlying the role of mGlu1 receptors
on extinction of fear conditioning remain to be established, our
ﬁnding that large mGlu1aþ ITC neurons are recipient of heavy
innervation by inputs from the thalamus, BA andmPFC as well as by
afferents enriched in group III mGlu receptors, which themselves
inﬂuence fear extinction, identiﬁes them as a potential key
component of the neural networks underlying fear extinction.
Future studies are warranted to assess the projections and targets
of these neurons.
5. Conclusions
The current pharmacotherapy of anxiety disorders primarily
targets the GABAergic and serotonergic systems. However, these
treatments appear of limited efﬁcacy (Pull, 2007) underlying the
need for treatments that address novel mechanisms. In addition,
pharmacological treatments that could be used in adjunct to
behavioural therapy to facilitate extinction would be of particularly
clinical interest. Our study substantiates the view that mGlu7
receptor agonists or positive allosteric modulators may represent
such a class of drugs. Moreover, the elucidation of how and where,
at the synaptic level, group III mGlu receptors may impinge on the
neural pathways within the amygdala underlying inhibition of fear,
will help determining the therapeutic value of drugs acting at these
receptors.
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